This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CHB-111

Endo International plc

Drug Names(s): HepaVaxx B

Description: HepaVaxx B vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to target dendritic cells. In preclinical testing, HepaVaxx B has produced both cellular and humoral immune responses. ViRexx believes that the development of humoral and cellular responses may be effective in clearing the virus from patients with chronic hepatitis B infection.

Deal Structure: HepaVaxx B vaccine was originally developed by ViRexx.

Paladin and ViRexx
In December 2008, Paladin Labs announced that it acquired all the outstanding shares ViRexx Medical Corp.

Endo and Paladin
In November 2013, Endo announced that it has reached a definitive agreement to acquire Paladin in a stock and cash transaction valued at approximately $1.6 billion of which approximately 98% will be paid in shares of stock. Pursuant to the acquisition, each of Endo and Paladin will be acquired by a newly-formed Irish holding company (New Endo). Following completion of the transaction, New Endo will be led by Endo's current management team. Paladin will be a separate operating company under New Endo. Its Canadian operations will continue under the Paladin Labs name.

In February 2014, Paladin announced the completion of the indirect acquisition by Endo of all of the outstanding shares of the Corporation. Under the terms of the Arrangement, Endo and...See full deal structure in Biomedtracker


CHB-111 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug